Investment Focus

We invest in companies where we can make the greatest impact. Typically, that means we invest in seed and early-stage biotech companies, based primarily in North America and Europe, who are working on novel therapeutics, platform technologies, diagnostics, or vaccines.

 

Platform Technologies

Regenerative medicine

Synthetic biology

Microbiome

Gene therapy

Nucleic acid medicine

Novel Theraputics

Neurodegeneration

Immunology

Inflammation

Rare disease

Diagnostics

Neurodegenerative Disorders

 

Meet our team

Our team of PhDs has rich experience in both business and science, and works closely with our biotech entrepreneurs to bring their innovative products to market faster.

 
 
JM_Headshot.jpg

Jeffrey Moore
President

Dr. Jeff Moore joined MPH in 2008 with notable professional experience as a scientist, businessman, and investor. Dr. Moore specializes in biochemistry, infectious disease and immunology, and works closely with our early stage portfolio companies.

Current Companies: F-star, Forge, QurAlis

Education

BSc in Biology
University of New Brunswick/University College London

DPhil in Pathology
University of Oxford

Postdoc in Biochemistry and Molecular Biology
Harvard Medical School

MBA
Massachusetts Institute of Technology

Class 10
Kauffman Fellow

Professional Experience

Research Corporation Technologies, Millennium Pharmaceuticals, Scriptgen

 
TO_Headshot.jpg
 

Tsuyoshi Okuno
Director

Dr. Tsuyoshi Okuno joined MPH in 2019 with a diverse background in corporate strategic planning, portfolio strategy, research management, and regenerative medicine. He leverages his extensive pharmaceutical development experience to help support our portfolio companies.

Education

Master of Pharmaceutical Sciences
Osaka University

PhD in Veterinary Science
Osaka Prefecture University

MBA
Osaka Prefecture University

Professional Experience

Mitsubishi Tanabe Pharma Corporation

 
LT_Headshot.jpg

Laura Tadvalkar
Principal

Dr. Laura Tadvalkar joined MPH in 2017. At MPH, she focuses on investments in platform technologies and neuroscience, leveraging her expertise in chemical biology, mitochondrial physiology, and metabolism. Dr. Tadvalkar also works closely with portfolio companies to support business development and portfolio strategy.

Current Companies: Ribometrix, Sonde, QurAlis

Education

BS in Chemistry
Yale University

PhD in Chemical Biology
Harvard University

Class 23
Kauffman Fellow

Professional Experience

Clarion Healthcare